Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) were down 9.6% on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $10.00 to $7.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Recursion Pharmaceuticals traded as low as $2.89 and last traded at $2.8750. 12,297,236 shares traded hands during trading, a decline of 37% from the average daily volume of 19,608,584 shares. The stock had previously closed at $3.18.
Several other research firms have also issued reports on RXRX. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Monday, October 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, October 15th. Morgan Stanley set a $5.90 price target on shares of Recursion Pharmaceuticals in a research report on Friday, October 16th. Finally, Wall Street Zen raised shares of Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $7.58.
View Our Latest Report on Recursion Pharmaceuticals
Insider Activity
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC bought a new stake in Recursion Pharmaceuticals in the 1st quarter valued at $7,370,000. Bank of New York Mellon Corp lifted its stake in Recursion Pharmaceuticals by 29.3% in the 1st quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock worth $4,490,000 after purchasing an additional 331,048 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Recursion Pharmaceuticals by 18.2% during the 1st quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after purchasing an additional 384,486 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of Recursion Pharmaceuticals by 15.2% during the 1st quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock valued at $8,015,000 after purchasing an additional 344,035 shares during the last quarter. Finally, California State Teachers Retirement System grew its position in shares of Recursion Pharmaceuticals by 64.0% during the first quarter. California State Teachers Retirement System now owns 574,637 shares of the company’s stock valued at $1,764,000 after purchasing an additional 224,332 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.
Recursion Pharmaceuticals Price Performance
The stock has a market cap of $1.69 billion, a PE ratio of -3.02 and a beta of 1.15. The stock has a 50-day moving average price of $3.75 and a two-hundred day moving average price of $3.47.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last issued its earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.22). The firm had revenue of $18.55 million for the quarter, compared to analysts’ expectations of $14.81 million. Recursion Pharmaceuticals had a negative return on equity of 47.85% and a negative net margin of 697.15%. During the same period in the previous year, the firm posted ($0.36) earnings per share. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -0.89 earnings per share for the current year.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.
Featured Stories
- Five stocks we like better than Recursion Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
